Ambit Biosciences (AMBI) announces the presentation of data from a Phase 2 study of the FLT3...


Ambit Biosciences (AMBI) announces the presentation of data from a Phase 2 study of the FLT3 inhibitor quizartinib and says that based on the "positive" results and "ongoing discussions with the FDA," the company plans to initiates a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia in H1 2014. Shares +7.35% premarket. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs